𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells

✍ Scribed by Konecny, G E; Venkatesan, N; Yang, G; Dering, J; Ginther, C; Finn, R; Rahmeh, M; Fejzo, M Schoenberg; Toft, D; Jiang, S-W

Book ID
109999439
Publisher
Nature Publishing Group
Year
2008
Tongue
English
Weight
234 KB
Volume
98
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The dual EGFR/HER-2 tyrosine kinase inhi
The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38
✍ Melissa J. LaBonte; Philipp C. Manegold; Peter M. Wilson; Will Fazzone; Stan G. πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 French βš– 482 KB

## Abstract Members of the human epidermal receptor (HER) family are frequently associated with aggressive disease and poor prognosis in multiple malignancies. Lapatinib is a dual tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) and HER‐2. This study evaluated the the

Lapatinib, a dual HER1/HER2 tyrosine kin
Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth
✍ Alejandro Vazquez-Martin; Cristina Oliveras-Ferraros; Silvia CufΓ­; Sonia Del Bar πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 252 KB

## Abstract The ultimate biological and clinical meaning of shed HER2 extracellular domain (ECD) has remained largely unclear until recently. Oversecretion of soluble HER2 ECD has been shown to inhibit growth of HER2‐overexpressing cancer cells by promoting HER2 ECD dimerization with HER transmembr